WallStSmart

Akanda Corp (AKAN)vsHaleon plc (HLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Haleon plc generates 1318237% more annual revenue ($11.03B vs $836,660). HLN leads profitability with a 15.1% profit margin vs -266.3%. AKAN trades at a lower P/E of 0.0x. HLN earns a higher WallStSmart Score of 63/100 (C+).

AKAN

Avoid

24

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 1/9

HLN

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 7.5Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.37

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AKAN3 strengths · Avg: 9.3/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.9%8/10

Revenue surging 21.9% year-over-year

HLN4 strengths · Avg: 8.5/10
EPS GrowthGrowth
92.0%10/10

Earnings expanding 92.0% YoY

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.2%8/10

Strong operational efficiency at 23.2%

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

Areas to Watch

AKAN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$9.04M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-948.4%2/10

ROE of -948.4% — below average capital efficiency

HLN2 concerns · Avg: 4.0/10
PEG RatioValuation
2.354/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : AKAN

The strongest argument for AKAN centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.

Bull Case : HLN

The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.

Bear Case : AKAN

The primary concerns for AKAN are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : HLN

The primary concerns for HLN are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

AKAN profiles as a growth stock while HLN is a value play — different risk/reward profiles.

AKAN carries more volatility with a beta of 14.61 — expect wider price swings.

AKAN is growing revenue faster at 21.9% — sustainability is the question.

HLN generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

HLN scores higher overall (63/100 vs 24/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akanda Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Akanda Corporation. The company is headquartered in New Romney, the United Kingdom.

Haleon plc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.

Visit Website →

Want to dig deeper into these stocks?